. Author manuscript; available in PMC: 2017 Jan 1.

Published in final edited form as: Antivir Ther. 2014 Dec 23;21(2):107–116. doi: 10.3851/IMP2927

Table 2.

Data before and after 12 weeks of treatment with growth hormone and/or rosiglitazone or double placebo for all subjects with MRS scan of the liver.

	rhGH			Rosi			rhGH + Rosi			Double placebo			p^*
	Baseline	Week 12	P^‡	Baseline	Week 12	P	Baseline	Week 12	P	Baseline	Week 12	P	Baseline	Week 12
n	7			6			12			6
%female	33			11			29			33			0.41°	.
Age, yr	48.7±6.8	.	.	46.7±8.6	.	.	48.6±11.7	.	.	47.2±5.9	.	.	0.97	.
Height, cm	171.3±11.8	.	.	171.1±4.5	.		170.8±7.5	.		169.5±53.7	.	.	0.98	.
Weight, kg	90.4±8.7	90.8±9.4	0.72	81.3±8.3	83.0±9.8	0.077	86.8±13.6	87.6±13.8	0.35	82.1±20.6	82.3±18.8	0.93	0.68	0.93
BMI, kg/m²	31.0±3.7	31.1±3.2	0.86	27.8±3.4	28.4±4.0	0.076	29.7±3.8	30.0±3.7	0.40	28.7±5.5	28.8±5.0	0.90	0.57	0.95
DXA lean, kg	55.9±8.8	59.2±9.8^a	0.016	57.0±6.8	57.0±6.1^a	0.98	56.9±11.0	60.5±11.8^a	0.0030	50.2±14.0	50.5±11.5^b	0.90	0.89	0.07
DXA fat, kg	31.2±8.5	28.4±7.5^a	0.0094	21.3±6.7	23.2±7.0^b	0.13	26.4±8.4	24.0±8.8^a,b	0.0072	28.6±10.6	28.4±10.9^b	0.78	0.20	0.006
VAT, L	4.4±2.0	3.5±1.7^a	0.0038	5.3±2.1	5.5±2.0^b	0.55	5.9±2.5	4.5±1.4^a,b	0.013	5.6±2.4	5.7±2.5^b	0.94	0.58	0.0086
SAT, L	29.7±10.4	29.4±9.4	0.58	19.5±5.1	20.0±6.9	0.63	24.9±9.2	24.8±8.2	0.90	26.0±10.3	26.0±10.9	0.99	0.27	0.99
TAT, L	36.5±7.2	35.8±6.6	0.40	33.5±5.0	34.7±4.5	0.047	32.1±9.1	31.0±7.0	0.47	33.0±9.8	33.2±10.8	0.92	0.73	0.56
SMM, L	28.1±4.1	30.5±6.0	0.18	28.4±4.1	28.7±4.0	0.46	28.5±6.9	30.7±8.2	0.10	27.0±7.7	27.9±7.6	0.24	0.97	0.64
QUICKI	0.31±0.03	0.29±0.02	0.09	0.31±0.02	0.29±0.02	0.06	0.30±0.01	0.29±0.02	0.16	0.30±0.02	0.30±0.03	0.50	0.54	0.29
Hepatic fat, %	15.9±10.3	13.0±8.2	0.46	27.3±17.5	28.2±18.7	0.80	25.4±21.0	19.2±19.2	0.038	39.1±22.1	38.8±20.6	0.96	0.20	0.26

ANOVA except where otherwise indicated; controlled for baseline value at Week 12.

^‡

Paired t-test °Fisher's exact test

Letters indicate which intervention groups are similar